MAGIC算法概率可预测急性GVHD二线治疗的治疗反应和长期结局
该研究分析了17个中心2016至2021年间167例急性GVHD患者启动二线系统治疗时的临床数据和血清样本。卢可替尼组第28天总缓解率高于非卢可替尼组(55% vs 31%,P=0.003),2年非复发死亡率更低(35% vs 61%,P=0.002)。生物标志物分析显示卢可替尼的获益仅见于二线治疗开始时MAGIC算法概率低的患者。
要点
- 卢可替尼组第28天总缓解率55% vs 非卢可替尼组31%(P=0.003)。
- 低MAGIC算法概率患者中,卢可替尼组2年非复发死亡率12% vs 非卢可替尼组41%(P=0.016)。
- 高MAGIC算法概率患者无论接受何种治疗,2年非复发死亡率均高(67% vs 80%,P=0.65)。
核心结论
- 急性GVHD二线系统治疗时测定的MAGIC算法概率可预测治疗反应和非复发死亡率。
- 高MAGIC算法概率患者无论选择何种治疗结局均差,卢可替尼似乎主要使低MAGIC算法概率患者获益。
研究设计与样本
- 分析了2016年至2021年间来自MAGIC国际联盟17个中心的167例急性GVHD患者启动二线系统治疗时的临床数据和血清样本。
- 62例接受以卢可替尼为基础的治疗,102例接受其他系统药物治疗。
主要发现
- 卢可替尼组第28天总缓解率高于非卢可替尼组(55% vs 31%,P=0.003)。
- 卢可替尼组2年非复发死亡率点估计值低于非卢可替尼组(35% vs 61%,P=0.002)。
- 低MAGIC算法概率患者中,卢可替尼组2年非复发死亡率点估计值低于非卢可替尼组(12% vs 41%,P=0.016)。
- 高MAGIC算法概率患者中,卢可替尼组与非卢可替尼组2年非复发死亡率点估计值分别为67%和80%(P=0.65)。
- 里程碑分析显示第28天反应与非复发死亡率的关系在很大程度上取决于二线治疗开始时的MAGIC算法概率水平。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The significance of biomarkers in second-line treatment for acute graft-versus-host disease (GVHD) has not been well characterized. We analyzed clinical data and serum samples at the initiation of second-line systemic treatment of acute GVHD from 167 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC) between 2016 and 2021. Sixty-two patients received ruxolitinib-based therapy, whereas 102 received other systemic agents. In agreement with prospective trials, ruxolitinib resulted in a higher day 28 (D28) overall response Frate than nonruxolitinib therapies (55% vs 31%, P = .003) and patients who received ruxolitinib had significantly lower nonrelapse mortality (NRM) than those who received nonruxolitinib therapies (point estimates at 2-year: 35% vs 61%, P = .002). Biomarker analyses demonstrated that the benefit from ruxolitinib was observed only in patients with low MAGIC algorithm probabilities (MAPs) at the start of second-line treatment. Among patients with a low MAP, those who received ruxolitinib experienced significantly lower NRM than those who received nonruxolitinib therapies (point estimates at 2-year: 12% vs 41%, P = .016). However, patients with high MAP experienced high NRM regardless of treatment with ruxolitinib or nonruxolitinib therapies (point estimates at 2-year: 67% vs 80%, P = .65). A landmark analysis demonstrated that the relationship between the D28 response and NRM largely depends on the MAP level at the initiation of second-line therapy. In conclusion, MAP measured at second-line systemic treatment for acute GVHD predicts treatment response and NRM. The outcomes of patients with high MAP are poor regardless of treatment choice, and ruxolitinib appears to primarily benefit patients with low MAP.
引用
- DeFilipp Z, Kim HT, Spyrou N, et al. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD. Blood Adv. 2024. PMID: 38640197. doi:10.1182/bloodadvances.2024012561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。